International Journal of Science and Research Archive
eISSN: 2582-8185
Cross Ref DOI: 10.30574/ijsra
Journal homepage: https://ijsra.net/

(REVIEW ARTICLE)

Check for updates

The role of Artificial Intelligence models in clinical decision support for infectious disease diagnosis and personalized treatment planning

Victor Akachukwu Ibiam [1], Lauretta Ekanem Omale [2, *] and Oladimeji Taiwo [3]

[1] *Department of Health Science, Western Illinois University, Illinois, United State of America.*
[2] *Department of Community Psychology, College of Psychology and Behavioral Sciences, National Louis University. Chicago Illinois.*
[3] *Department of Health and Wellness Services, Western Illinois University, Illinois, United States of America.*

International Journal of Science and Research Archive, 2025, 14(03), 1337-1347

Publication history: Received on 10 February 2025; revised on 16 March 2025; accepted on 19 March 2025

Article DOI: https://doi.org/10.30574/ijsra.2025.14.3.0769

Abstract

Artificial intelligence is revolutionizing infectious disease management through innovative approaches to diagnosis, treatment optimization, and epidemiological surveillance. This systematic review examines AI applications in clinical decision support systems, evaluating their implementation across diverse healthcare settings while identifying critical adoption barriers. Recent advancements demonstrate remarkable success in rapid pathogen identification, early warning systems for conditions like sepsis, and personalized antimicrobial selection based on local resistance patterns. Despite these promising developments, significant challenges persist in translating AI solutions into clinical practice, including data quality issues, implementation barriers, and ethical concerns regarding algorithmic fairness and global health equity. Looking forward, explainable AI architectures, federated learning approaches, and treatment simulation through digital twins show potential for transforming care delivery, particularly in resource-limited settings. We propose targeted recommendations across three domains: standardized validation methodologies, comprehensive stakeholder engagement strategies, and equity-centered development frameworks. Successful integration requires coordinated efforts among healthcare organizations, researchers, policymakers, and clinicians to ensure AI enhances rather than complicates clinical decision-making. With appropriate attention to technical rigor, implementation science, and ethical considerations, AI-based systems can become valuable tools in combating infectious diseases while optimizing resource utilization.

Keywords: Clinical Decision Support Systems; Artificial Intelligence; Infectious Disease Diagnosis; Personalized Medicine; Antimicrobial Stewardship; Predictive Modeling

1. Introduction

The global burden of infectious diseases remains substantial despite significant advances in prevention, diagnosis, and treatment over the past century. With the emergence of new pathogens, the re-emergence of old threats, and the alarming rise of antimicrobial resistance, healthcare systems worldwide face increasingly complex challenges in infectious disease management [1]. In this context, artificial intelligence (AI) has emerged as a potentially transformative technology that could fundamentally alter how we approach infectious disease diagnosis and treatment planning.

Clinical decision support systems (CDSS) powered by AI offer the promise of augmenting human capabilities by rapidly processing vast amounts of heterogeneous data to generate actionable insights. These systems can potentially identify patterns invisible to the human eye, predict disease trajectories, optimize treatment regimens, and personalize care

* Corresponding author: Lauretta Ekanem Omale

based on individual patient characteristics [2]. As healthcare generates unprecedented volumes of data, AI approaches offer a means to extract meaningful information that can guide clinical decision-making.

The application of AI in infectious disease management spans the entire care continuum, from diagnosis through machine learning algorithms analyzing multiple data types, to treatment planning where AI models can predict antimicrobial susceptibility and treatment responses [3]. Additionally, AI-based systems can support resource allocation, outbreak prediction, and public health interventions at the population level [4].

This review aims to critically evaluate the current state of AI applications in infectious disease diagnosis and personalized treatment planning, examining both promising advances and significant challenges. We explore the technical foundations, implementation barriers, and ethical considerations that must be carefully navigated for AI to fulfil its promise in infectious disease management. By synthesizing existing evidence and identifying key research priorities, this review seeks to provide a comprehensive overview of how AI is reshaping clinical decision support for infectious diseases and the path forward for this rapidly evolving field.

2. Current State of AI in Infectious Disease Management

The application of artificial intelligence in infectious disease management has evolved rapidly, moving from theoretical concepts to clinical implementation across various healthcare settings. This section examines the current landscape of AI applications in diagnosis, treatment planning, and epidemiological monitoring.

2.1. Diagnostic Applications

Image-based diagnostic systems represent one of the most mature AI applications. Deep learning models for tuberculosis detection from chest radiographs achieve sensitivity and specificity exceeding 90%, comparable to radiologists [5]. Similar approaches have been developed for malaria parasites, pneumonia patterns, and COVID-19 manifestations, enabling systematic screening programs in resource-limited settings [6].

Laboratory data interpretation systems analyze clinical parameters to detect conditions like sepsis hours before clinical manifestation. Platforms like Epic Sepsis Model analyze vital signs, laboratory values, and medication data to generate early warning risk scores [7]. These systems have been implemented in hundreds of hospitals worldwide, showing improvements in intervention rates and mortality reduction.

Pathogen identification has been revolutionized through AI integration with molecular diagnostics. Advanced algorithms analyze metagenomic sequencing data to rapidly identify pathogens from complex clinical samples, reducing time to results from days to hours [8]. AI-powered symptom-based diagnostic algorithms are expanding in primary care settings, helping distinguish between viral and bacterial infections [9].

2.2. Treatment Decision Support

Antimicrobial stewardship has been enhanced by AI systems analyzing local resistance patterns and patient characteristics to suggest optimal therapy. These platforms integrate microbiology results and patient information to predict resistance probabilities, helping clinicians select appropriate initial therapy while avoiding unnecessary broad-spectrum agents [10]. Implementation studies demonstrate reductions in inappropriate prescribing and shorter time to appropriate therapy [11].

Treatment response prediction models integrate patient characteristics and early clinical markers to forecast outcomes. These approaches show particular value in tuberculosis management, where models incorporating clinical, radiographic, and molecular data identify high-risk patients [12]. Similar applications exist for HIV, hepatitis C, and complicated urinary tract infections [13].

Dosing optimization through machine learning algorithms incorporates patient-specific factors to recommend individualized antimicrobial regimens. These systems are particularly valuable for drugs with narrow therapeutic windows, such as vancomycin and aminoglycosides [14]. Adverse event prediction systems analyze medication regimens and patient characteristics to identify individuals at elevated risk for specific complications [15].

2.3. Public Health Applications

Disease surveillance systems analyze diverse data streams including electronic health records, social media, and environmental sensors to detect outbreaks earlier than traditional methods. Systems like HealthMap and BlueDot successfully identified early signals of COVID-19 and other outbreaks, enabling rapid public health responses [16].

Contact tracing and transmission risk modeling have advanced through AI approaches during the COVID-19 pandemic. Machine learning algorithms analyze mobility data, social networks, and individual risk profiles to identify high-risk exposures [17]. More sophisticated implementations incorporate genomic data to distinguish between separate introduction events and community transmission chains [18].

Resource allocation optimization helps predict healthcare capacity needs and optimize intervention distribution. During COVID-19, these models helped forecast ventilator needs and hospital bed requirements, enabling proactive resource redistribution. Similar approaches optimize vaccine distribution and testing unit placement, becoming essential components of modern outbreak response [19].

2.4. Implementation Landscape

Adoption patterns vary across settings, with high-income countries showing more rapid implementation, particularly in academic centres. Image-based diagnostics and early warning tools have achieved broader penetration in U.S. hospitals, while antimicrobial stewardship AI tools are also utilized in hospitals [20]. Resource-limited settings focus on specific high-impact applications addressing critical gaps in specialist availability.

Integration approaches include passive decision support, active alerts, or automated triage. Active alert systems automatically notify clinicians when risk thresholds are exceeded, showing higher utilization rates while requiring careful balance of sensitivity and specificity. Successful implementations typically involve attention to user interface design and iterative refinement based on clinician feedback [21].

Regulatory frameworks continue evolving, with the FDA establishing a Digital Health Center of Excellence and the EU implementing specific provisions for medical device software [22]. Regulatory approaches stratify oversight based on risk level, with common requirements including clinical validation, algorithm explainability, and plans for managing updates [23]. Regulatory bodies increasingly collaborate to harmonize approaches while maintaining safety standards.

3. Technical Approaches and Methodologies

3.1. Machine Learning Techniques

Supervised learning forms the backbone of many infectious disease management applications, where models are trained on labeled datasets to classify patients or predict outcomes. These models excel at tasks like diagnosis prediction, risk stratification, and treatment response forecasting, learning from historical cases to make predictions about new patients. The approach is particularly effective when clear outcome labels are available, such as confirmed diagnoses or treatment responses [24].

Unsupervised learning techniques identify patterns in data without predefined labels, proving valuable for discovering novel disease phenotypes or patient clusters. These methods can reveal previously unrecognized disease subtypes or patient groups that might benefit from different management approaches. This approach has been particularly useful in understanding complex conditions like Alzheimer’s disease, where traditional clinical definitions may not capture all relevant patient subgroups [25].

Deep learning applications, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs) have revolutionized medical imaging analysis and temporal data processing. CNNs excel at image-based diagnostics, while RNNs and transformer models effectively analyze sequential clinical data [26]. Reinforcement learning represents an emerging approach for optimizing treatment regimens by modeling sequential decision-making in patient care, though its clinical applications remain primarily experimental due to ethical considerations[27].

3.2. Data Sources and Integration

Electronic Health Records (EHRs) serve as a primary data source, containing rich longitudinal information including symptoms, laboratory values, medications, and outcomes. These records provide comprehensive patient histories and treatment trajectories, though data quality and standardization remain significant challenges. The temporal nature of EHR data makes it particularly valuable for understanding disease progression and treatment responses[28].

Imaging data, including X-rays, CT scans, and microscopy images, provides crucial visual diagnostic information. When combined with genomic data from pathogen sequencing, host genetic factors, and microbiome composition, these sources offer unprecedented insight into disease mechanisms and treatment responses [29]. Modern AI systems increasingly incorporate epidemiological data on disease prevalence, transmission patterns, and antimicrobial resistance to provide context-aware recommendations.

The integration of wearable and sensor data represents an emerging frontier, enabling continuous monitoring of vital signs and other physiological parameters. Successfully combining these heterogeneous data types remains a significant challenge but offers potential for more comprehensive and accurate decision support [30]. Integration efforts must address issues of data standardization, temporal alignment, and varying data quality while maintaining patient privacy and data security.

4. Challenges and Limitations in AI Implementation

Despite promising advances in AI applications for infectious disease management, significant challenges remain that hamper widespread implementation and optimal utilization. These challenges span technical, clinical, and socioeconomic domains.

4.1. Data Quality and Availability Challenges

Data fragmentation represents a fundamental obstacle to developing robust AI systems. Clinical information often resides in disparate systems, limiting the comprehensiveness of training datasets and creating challenges for real-time integration. Interoperability issues persist despite standardization efforts, with proprietary formats and inconsistent implementation of standards impeding seamless data flow [31].

Data quality concerns present significant challenges, including missing data, inconsistent documentation practices, and errors introduced during clinical workflows. These issues can introduce biases into model training and reduce performance during deployment, particularly in resource-limited settings where electronic documentation may be incomplete [32].

Bias in training data reflects existing disparities in healthcare access and treatment approaches. Models trained on these datasets risk perpetuating or amplifying these biases [33]. Privacy and security concerns add complexity, as infectious disease data often contains sensitive information subject to regulatory protections [34].

4.2. Model Development and Validation Challenges

Generalizability remains a significant challenge for AI systems, with models often performing well in development environments but experiencing substantial degradation when deployed in new settings. Contributing factors include demographic differences, variations in disease prevalence, and institution-specific practice patterns. Temporal drift occurs as clinical practices evolve, requiring continuous model updating [35].

Interpretability presents another critical challenge, particularly for complex models like deep neural networks. Clinicians demand transparency in decision support tools, wanting to understand not just what the model predicts but why. Various approaches have emerged, including attention mechanisms and hybrid architectures, though achieving both high performance and sufficient interpretability remains challenging [36].

Validation methodology faces practical barriers including cost, time requirements, and the rapid evolution of AI systems. Resource requirements for model development and maintenance create substantial barriers to implementation, particularly in resource-limited settings [37].

4.3. Clinical Implementation Barriers

Workflow integration challenges often create friction points where technology disrupts rather than enhances clinical care. Common issues include additional authentication steps, redundant documentation, and alert timing that doesn't align with decision points. Successful integration requires thorough workflow analysis and user-centered design principles [38].

Clinician adoption barriers encompass professional, psychological, and social factors. Trust represents a fundamental prerequisite, influenced by transparency of algorithm development and alignment with clinical reasoning. Resistance may stem from perceived threats to professional autonomy or concerns about increased liability [39].

Infrastructure limitations present substantial challenges, particularly in resource-constrained settings. Basic requirements include reliable electricity, internet connectivity, and technical support capacity [40]. Regulatory uncertainties create additional barriers, as the rapidly evolving nature of AI applications has outpaced regulatory frameworks [41].

Healthcare procurement policies within Medicare and Medicaid present unique challenges for AI implementation in infectious disease management. As highlighted in a comprehensive analysis of CMS procurement mechanisms, the lengthy approval processes and stringent validation requirements can significantly delay adoption of innovative technologies [42]. These administrative hurdles, while designed to ensure patient safety, often lag behind the rapid advancement of AI technologies. Additionally, the complex interplay between federal Medicare regulations and state-level Medicaid procurement policies creates a fragmented landscape that complicates wide-scale deployment of standardized AI solutions across multiple jurisdictions.

5. Ethical and Social Considerations

5.1. Algorithmic Fairness

AI systems in infectious disease management face significant fairness problems stemming from deeply entrenched biases in healthcare data. Historical underrepresentation of minorities, socioeconomic access disparities, and inconsistent documentation practices create fundamental data quality issues. Models trained on these biased datasets consistently demonstrate reduced accuracy for certain populations and systematic risk assessment errors that can directly impact patient care. Studies examining deployed AI systems have documented performance gaps of 15-30% between demographic groups for common infectious disease applications [43].

The technical complexity of identifying these biases presents another substantial challenge. Many algorithmic biases remain invisible until deployment in diverse settings, where performance disparities emerge. Current validation approaches often fail to detect demographic-specific performance issues, particularly when certain populations represent a small fraction of the training or validation datasets. Even when biases are identified, correcting them without introducing new imbalances requires sophisticated statistical approaches that many development teams lack the expertise to implement [44].

5.2. Transparency and Patient Rights

The black-box nature of many AI systems creates fundamental challenges for meaningful transparency. Complex deep-learning models used in infectious disease diagnostics operate through millions of parameters that cannot be easily explained to patients or clinicians. This opacity complicates clinical decision-making, as healthcare providers cannot fully evaluate the reasoning behind AI recommendations when discussing options with patients[45].

Patient understanding of AI's role in their care decisions presents another significant problem. Current disclosure practices vary widely, with many patients unaware when AI influences their diagnosis or treatment. When patients do receive disclosure, studies indicate high levels of confusion about what algorithm use means for their care. This transparency gap becomes particularly problematic for infectious disease management, where decisions about isolation or antimicrobial therapy carry significant consequences [46].

5.3. Global Health Equity

The concentration of AI development in high-resource settings has created a growing technological divide. Over 80% of published AI research in infectious disease management comes from just five high-income countries, while regions with the highest disease burden have minimal representation in dataset development or algorithm validation. This geographical imbalance leads to models that perform poorly in low-resource contexts where they could provide the greatest benefit [47].

Infrastructure requirements present another substantial barrier. Many promising AI applications demand high-speed internet connectivity, substantial computing resources, and specialized technical expertise—all frequently lacking in regions with the greatest infectious disease challenges. The cost of implementation often proves prohibitive, with estimates suggesting that deploying comprehensive AI systems requires initial investments exceeding annual per-capita healthcare spending in many low-income countries.[48]

The mismatch between AI solution design and local needs further exacerbates inequity problems. Systems developed for tertiary care hospitals in high-income countries often prove impractical for primary care settings in low-resource environments. This fundamental disconnect threatens to widen rather than narrow global healthcare disparities as AI adoption accelerates in well-resourced settings while remaining inaccessible elsewhere[49].

6. Future Directions and Opportunities

The field of AI in infectious disease management continues to evolve rapidly, with emerging technologies promising to address current limitations while enabling novel applications. This section explores key technological innovations, clinical applications in development, and priority areas for future research.

6.1. Technological Innovations

Explainable AI represents a critical frontier for advancing clinical applications. Current research focuses on developing neural network architectures that provide human-interpretable explanations while maintaining high performance. Approaches such as attention mechanisms and hybrid models combining deep learning with rule-based systems are showing promise in transforming "black box" models into "glass box" systems [50].

Federated learning emerges as a promising approach to developing robust models while preserving data privacy. This paradigm enables algorithm training across multiple institutions without sharing raw patient data. Early applications have demonstrated feasibility for developing antimicrobial resistance prediction models and sepsis detection algorithms [51].

Continuous learning systems represent the most transformative frontier in clinical AI development. Unlike static models, these systems update based on new data and outcomes, enabling adaptation to evolving clinical practices and emerging pathogens. While substantial technical and regulatory challenges remain, early implementations have employed human-in-the-loop approaches where clinicians validate proposed model updates before deployment [52].

6.2. Clinical Applications on the Horizon

Precision antimicrobial therapy guided by AI promises to address the dual challenges of optimizing individual treatment outcomes while minimizing resistance development. Next-generation systems will integrate host genomic factors, pathogen genomics, and patient-specific comorbidities to generate personalized treatment recommendations. Early research demonstrates feasibility in predicting treatment response for tuberculosis, HIV, and invasive fungal infections [53].

Digital twins for treatment simulation combine mechanistic disease models with patient-specific data to create virtual patient representations. These systems integrate pharmacokinetic models and pathogen characteristics to simulate intervention outcomes. Early examples include viral dynamic models for hepatitis C and HIV, with growing applications for optimizing complex treatment decisions [54].

Virtual infectious disease consultation powered by AI may help address specialist shortages, particularly in resource-limited settings. These systems would integrate knowledge bases with advanced natural language processing to provide specialist-level guidance for complex cases. Early prototypes show promise for complicated infections, potentially transforming access to specialist-level care globally [55].

The economic implications of emerging AI applications demand careful evaluation, particularly for healthcare organizations serving Medicare and Medicaid beneficiaries. Analysis of strategic procurement practices highlights how cost containment pressures influence technology adoption decisions in these settings [56]. Their research suggests that next-generation applications like precision antimicrobial therapy and virtual consultation platforms must demonstrate clear economic value propositions to gain traction in public insurance contexts. Developers should consider tailoring implementation models that address the unique financial constraints and return-on-investment timelines typical in organizations with high Medicare/Medicaid payer mixes.

6.3. Research Priorities

Standardized validation approaches remain an urgent priority for advancing the field responsibly. Future research must develop frameworks for systematically evaluating AI systems across predictive performance, generalizability, fairness, and clinical impact. Multi-institutional validation studies employing consistent methodologies are needed to assess model performance across different settings [57].

Equity-focused development methodologies represent a critical research priority for ensuring AI benefits extend to all populations. Future work must establish best practices for identifying and mitigating bias throughout the AI lifecycle. Research is needed to develop techniques for evaluating performance across demographic groups despite underrepresentation [58].

Implementation science focused on AI integration into clinical workflows demands systematic evaluation of different approaches across diverse healthcare settings. Research examining how AI recommendations influence clinical decision-making could inform better system design and education strategies. Additionally, economic analyses examining total implementation costs would help healthcare organizations make informed investment decisions [59].

7. Recommendations for Research and Implementation

7.1. Standardization and Validation

Healthcare organizations and researchers must adopt standardized frameworks for AI model development and reporting. The TRIPOD-AI guidelines should serve as a foundation for documenting model development, validation, and performance metrics. This standardization will enable meaningful comparison across different AI solutions and facilitate evidence-based implementation decisions.

Multi-center, prospective validation studies should become the norm rather than the exception. These studies must span diverse healthcare settings and patient populations to ensure generalizability. Validation protocols should assess not only technical accuracy but also clinical utility, workflow integration, and impact on patient outcomes.

Quality assurance mechanisms for ongoing monitoring of AI system performance in real-world settings are essential. Organizations should establish clear protocols for detecting and addressing performance degradation, model drift, and unexpected behaviors. This includes regular audits of system recommendations and outcomes across different patient subgroups.

7.2. Stakeholder Engagement and Implementation

Early and sustained engagement of key stakeholders is crucial for successful AI implementation. Development teams should include clinicians, patients, ethicists, and regulatory experts from the initial planning stages through deployment. This collaborative approach helps ensure AI solutions address real clinical needs while meeting ethical and regulatory requirements.

Implementation science research should focus on identifying optimal strategies for integrating AI tools into clinical workflows. Studies should examine factors affecting adoption rates, user experience, and long-term sustainability. Special attention should be paid to resource-limited settings where implementation challenges may be more pronounced.

Change management strategies must address both technical and cultural aspects of AI adoption. Healthcare organizations should develop comprehensive training programs that build AI literacy while addressing concerns about automation bias and clinical autonomy. Regular feedback loops between users and developers can facilitate continuous improvement.

Public-private partnerships should be developed to address the unique implementation challenges within Medicare and Medicaid settings. As documented in recent analyses of healthcare procurement policies, these partnerships can help bridge the gap between technological innovation and administrative requirements within public insurance programs. By bringing together AI developers, healthcare administrators, and CMS officials, such collaborations could streamline validation processes while ensuring that AI solutions for infectious disease management meet the specific needs and constraints of Medicare and Medicaid populations.

7.3. Equity and Ethics

Equity-focused design principles must be embedded throughout the AI development lifecycle. Teams should proactively identify and mitigate potential sources of bias in training data, model architecture, and implementation approaches. This includes ensuring diverse representation in development teams and validation cohorts.

Transparency requirements should be established for AI systems used in clinical decision-making. Healthcare organizations must develop clear protocols for disclosing AI use to patients and explaining how algorithmic recommendations influence care decisions. Patient rights regarding AI-guided care should be explicitly defined and protected.

Resource allocation strategies should prioritize expanding AI benefits to underserved populations. International collaboration frameworks should facilitate knowledge sharing while respecting local healthcare contexts. Specific attention must be paid to developing AI solutions that function effectively in resource-limited settings where infectious disease burden is often highest.

Policy reforms should address disparities in AI access between Medicare/Medicaid-serving facilities and those primarily serving privately insured patients. Research on healthcare procurement within public insurance programs has identified significant technological gaps that threaten to exacerbate existing healthcare inequities. Targeted grant programs, technical assistance initiatives, and preferential procurement policies could help ensure that safety-net hospitals and clinics serving publicly insured populations have equal access to advanced AI tools for infectious disease management.

8. Conclusion

Artificial Intelligence stands at a pivotal moment in transforming infectious disease management, offering unprecedented opportunities to enhance diagnostic accuracy, optimize treatment decisions, and improve patient outcomes. This review has demonstrated the substantial progress made in developing and implementing AI-based clinical decision support systems, while also highlighting critical challenges that must be addressed for successful integration into healthcare practice.

The current landscape reveals both promising achievements and significant hurdles. AI systems have shown remarkable capability in areas such as rapid pathogen identification, treatment optimization, and disease surveillance. However, challenges persist in data quality, model interpretability, and clinical integration, requiring careful consideration as the field advances.

The path forward demands a balanced approach that embraces innovation while maintaining rigorous standards for patient safety and clinical efficacy. Success will require a coordinated effort across stakeholders, including healthcare organizations, researchers, policymakers, and clinicians. Particular attention must be paid to ensuring equitable access to AI-enabled healthcare solutions and preventing the amplification of existing healthcare disparities.

The evidence suggests that AI will not replace human clinical judgment but rather augment it, enabling more precise, timely, and personalized care decisions. By addressing current challenges while maintaining focus on patient benefit, the field can work toward a future where AI tools enhance rather than complicate clinical decision-making. This calls for continued investment in research, the development of standardized validation approaches, and careful attention to ethical implications while maintaining the fundamental goal of improving patient care through responsible innovation.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Nii-Trebi NI. Emerging and neglected infectious diseases: insights, advances, and challenges. BioMed research international. 2017;2017(1):5245021.

[2] Elhaddad M, Hamam S. AI-driven clinical decision support systems: an ongoing pursuit of potential. Cureus. 2024 Apr 6;16(4).

[3] Ganasegeran K, Abdulrahman SA. Artificial intelligence applications in tracking health behaviors during disease epidemics. InHuman Behaviour Analysis Using Intelligent Systems 2019 Nov 21 (pp. 141-155). Cham: Springer International Publishing.

[4] Zeng D, Cao Z, Neill DB. Artificial intelligence-enabled public health surveillance—from local detection to global epidemic monitoring and control. InArtificial intelligence in medicine 2021 Jan 1 (pp. 437-453). Academic Press.

[5] Kotei E, Thirunavukarasu R. A comprehensive review on advancement in deep learning techniques for automatic detection of tuberculosis from chest X-ray images. Archives of Computational Methods in Engineering. 2024 Jan;31(1):455-74.

[6] A. Computational intelligence methods in medical image-based diagnosis of COVID-19 infections. InComputational Intelligence Methods in COVID-19: Surveillance, Prevention, Prediction and Diagnosis 2020 Oct 7 (pp. 251-270). Singapore: Springer Singapore.

[7] Mahyoub MA, Yadav RR, Dougherty K, Shukla A. Development and validation of a machine learning model integrated with the clinical workflow for early detection of sepsis. Frontiers in Medicine. 2023 Nov YEŞİLYURT E. ARTIFICIAL INTELLIGENCE APPLICATIONS IN MICROBIOLOGY. HEALTH & SCIENCE 2024-III. 2024 Nov 1:43.

[8] Asif S, Zhao M, Li Y, Tang F, Ur Rehman Khan S, Zhu Y. AI-based approaches for the diagnosis of Mpox: challenges and future prospects. Archives of Computational Methods in Engineering. 2024 Aug;31(6):3585-617.

[9] Sakagianni A, Koufopoulou C, Feretzakis G, Kalles D, Verykios VS, Myrianthefs P. Using machine learning to predict antimicrobial resistance—a literature review. Antibiotics. 2023 Feb 24;12(3):452.

[10] Singer A, Fanella S, Kosowan L, Falk J, Dufault B, Hamilton K, Walus A. Informing antimicrobial stewardship: factors associated with inappropriate antimicrobial prescribing in primary care. Family practice. 2018 Aug;35(4):455-60.

[11] Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ open. 2021 Mar 1;11(3):e044687.

[12] Park H, Lo-Ciganic WH, Huang J, Wu Y, Henry L, Peter J, Sulkowski M, Nelson DR. Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. Hepatology. 2022 Aug;76(2):483-91.

[13] Ponthier L, Ensuque P, Destere A, Marquet P, Labriffe M, Jacqz-Aigrain E, Woillard JB. Optimization of vancomycin initial dose in term and preterm neonates by machine learning. Pharmaceutical research. 2022 Oct;39(10):2497-506.

[14] Tripoliti EE, Papadopoulos TG, Karanasiou GS, Naka KK, Fotiadis DI. Heart failure: diagnosis, severity estimation and prediction of adverse events through machine learning techniques. Computational and structural biotechnology journal. 2017 Jan 1;15:26-47.

[15] Choubey SK, Naman H. A review on use of data science for visualization and prediction of the covid-19 pandemic and early diagnosis of covid-19 using machine learning models. Internet of Medical Things for Smart Healthcare: Covid-19 Pandemic. 2020:241-65.

[16] Hang CN, Tsai YZ, Yu PD, Chen J, Tan CW. Privacy-enhancing digital contact tracing with machine learning for pandemic response: a comprehensive review. Big Data and Cognitive Computing. 2023 Jun 1;7(2):108.

[17] Babu CS, Praveen S. Swarm Intelligence and Evolutionary Machine Learning Algorithms for COVID-19: Pandemic and Epidemic Review. InDynamics of Swarm Intelligence Health Analysis for the Next Generation 2023 (pp. 83-103). IGI Global.

[18] Oluwafemi GO, Faith R, Badmus J, Luz H. Machine Learning for Healthcare Resource Allocation.

[19] Theriault-Lauzier P, Cobin D, Tastet O, Langlais EL, Taji B, Kang G, Chong AY, So D, Tang A, Gichoya JW, Chandar S. A responsible framework for applying artificial intelligence on medical images and signals at the point-of-care: the PACS-AI platform. Canadian Journal of Cardiology. 2024 Jun 15.

[20] Ivica J, Sanmugalingham G, Selvaratnam R. Alerting to acute kidney injury-Challenges, benefits, and strategies. Practical Laboratory Medicine. 2022 May 1;30:e00270.

[21] Bharadwaj MS. Regulatory Insights in Digital Health. InMulti-Sector Analysis of the Digital Healthcare Industry 2024 (pp. 164-197). IGI Global.

[22] Fraser AG, Biasin E, Bijnens B, Bruining N, Caiani EG, Cobbaert K, Davies RH, Gilbert SH, Hovestadt L, Kamenjasevic E, Kwade Z. Artificial intelligence in medical device software and high-risk medical devices–a review of definitions, expert recommendations and regulatory initiatives. Expert Review of Medical Devices. 2023 Jun 3;20(6):467-91.

[23] Obaido G, Mienye ID, Egbelowo OF, Emmanuel ID, Ogunleye A, Ogbuokiri B, Mienye P, Aruleba K. Supervised machine learning in drug discovery and development: Algorithms, applications, challenges, and prospects. Machine Learning with Applications. 2024 Sep 1;17:100576.

[24] Alexander N, Alexander DC, Barkhof F, Denaxas S. Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning. BMC Medical Informatics and Decision Making. 2021 Dec;21:1-3.

[25] Kumar RR, Shankar SV, Jaiswal R, Ray M, Budhlakoti N, Singh KN. Advances in Deep Learning for Medical Image Analysis: A Comprehensive Investigation. Journal of Statistical Theory and Practice. 2025 Mar;19(1):9.

[26] Smith B, Khojandi A, Vasudevan R. Bias in reinforcement learning: A review in healthcare applications. ACM Computing Surveys. 2023 Sep 15;56(2):1-7.

[27] Hemingway H, Asselbergs FW, Danesh J, Dobson R, Maniadakis N, Maggioni A, Van Thiel GJ, Cronin M, Brobert G, Vardas P, Anker SD. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. European heart journal. 2018 Apr 21;39(16):1481-95.

[28] [29] Mishra A, Tabassum N, Aggarwal A, Kim YM, Khan F. Artificial intelligence-driven analysis of antimicrobial-resistant and biofilm-forming pathogens on biotic and abiotic surfaces. Antibiotics. 2024 Aug 22;13(8):788.

[29] Das S. Applications of Sensor Technology in Healthcare. InRevolutionizing Healthcare Treatment With Sensor Technology 2024 (pp. 79-99). IGI Global.

[30] Esmaeilzadeh P. Challenges and strategies for wide-scale artificial intelligence (AI) deployment in healthcare practices: A perspective for healthcare organizations. Artificial Intelligence in Medicine. 2024 May 1;151:102861.

[31] Sukumar SR, Natarajan R, Ferrell RK. Quality of Big Data in health care. International journal of health care quality assurance. 2015 Jul 13;28(6):621-34.

[32] Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J, Gao G. Addressing algorithmic bias and the perpetuation of health inequities: An AI bias aware framework. Health Policy and Technology. 2023 Mar 1;12(1):100702.

[33] Elhoseny M, Thilakarathne NN, Alghamdi MI, Mahendran RK, Gardezi AA, Weerasinghe H, Welhenge A. Security and privacy issues in medical internet of things: overview, countermeasures, challenges and future directions. Sustainability. 2021 Oct 21;13(21):11645.

[34] Chen RJ, Chen TY, Lipkova J, Wang JJ, Williamson DF, Lu MY, Sahai S, Mahmood F. Algorithm fairness in ai for medicine and healthcare. arXiv preprint arXiv:2110.00603. 2021 Oct 1.

[35] Stiglic G, Kocbek P, Fijacko N, Zitnik M, Verbert K, Cilar L. Interpretability of machine learning-based prediction models in healthcare. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery. 2020 Sep;10(5):e1379.

[36] Dangi RR, Sharma A, Vageriya V. Transforming Healthcare in Low-Resource Settings With Artificial Intelligence: Recent Developments and Outcomes. Public Health Nursing. 2024 Dec 4.

[37] Owoyemi A. Development of a Framework and Checklist to Guide the Translation of AI Systems for Clinical Care (Doctoral dissertation, University of Illinois at Chicago).

[38] Reddy S, Shaikh S. The long road ahead: navigating obstacles and building bridges for clinical integration of artificial intelligence technologies. Journal of Medical Artificial Intelligence. 2024 Sep 10.

[39] Olugboja A, Agbakwuru EM. Bridging healthcare disparities in rural areas of developing countries: leveraging artificial intelligence for equitable access. In2024 International Conference on Artificial Intelligence, Computer, Data Sciences and Applications (ACDSA) 2024 Feb 1 (pp. 1-6). IEEE.

[40] Khan F. Regulating the revolution: a legal roadmap to optimizing AI in healthcare. Minn. JL Sci. & Tech.. 2023;25:49.

[41] Shodimu OA, Balogun AK, Ayodimeji-Alaba H, Francis C. The intersection of healthcare procurement and health insurance policies in Medicare and Medicaid administration.

[42] O'Brien N, Van Dael J, Clarke J, Gardner C, O'Shaughnessy J, Darzi A, Ghafur S. Addressing racial and ethnic inequities in data-driven health technologies.

[43] Chin MH, Afsar-Manesh N, Bierman AS, Chang C, Colón-Rodríguez CJ, Dullabh P, Duran DG, Fair M, Hernandez-Boussard T, Hightower M, Jain A. Guiding principles to address the impact of algorithm bias on racial and ethnic disparities in health and health care. JAMA Network Open. 2023 Dec 1;6(12):e2345050-.

[44] Smith H. Clinical AI: opacity, accountability, responsibility and liability. Ai & Society. 2021 Jun;36(2):535-45.

[45] Amann J, Blasimme A, Vayena E, Frey D, Madai VI, Precise4Q Consortium. Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. BMC medical informatics and decision making. 2020 Dec;20:1-9.

[46] Krones F, Walker B. From theoretical models to practical deployment: A perspective and case study of opportunities and challenges in AI-driven healthcare research for low-income settings. medRxiv. 2023 Dec 29:2023-12.

[47] Awuah WA, Kalmanovich J, Mehta A, Huang H, Yarlagadda R, Kundu M, Nasato M, Toufik AR, Olatunbosun PP, Isik A, Sikora V. Harnessing artificial intelligence to bridge the neurosurgery gap in low-income and middle-income countries. Postgraduate medical journal. 2023 Jul;99(1173):651-3.

[48] Mate AS. Actualizing Impact of AI in Public Health: Optimization of Scarce Health Intervention Resources in the Real World. Harvard University; 2023.

[49] Mesinovic M, Watkinson P, Zhu T. Explainable AI for clinical risk prediction: a survey of concepts, methods, and modalities. arXiv preprint arXiv:2308.08407. 2023 Aug 16.

[50] Zwiers LC, Grobbee DE, Uijl A, Ong DS. Federated learning as a smart tool for research on infectious diseases. BMC Infectious Diseases. 2024 Nov 21;24(1):1327.

[51] Li F, Wang S, Gao Z, Qing M, Pan S, Liu Y, Hu C. Harnessing artificial intelligence in sepsis care: advances in early detection, personalized treatment, and real-time monitoring. Frontiers in Medicine. 2025 Jan 6;11:1510792.

[52] Bauer DC, Wilson LO, Twine NA. Artificial Intelligence in Medicine: Applications, Limitations and Future Directions. InArtificial Intelligence in Medicine: Applications, Limitations and Future Directions 2022 Jun 17 (pp. 01-120). Singapore: Springer Nature Singapore.

[53] D'Orsi L, Capasso B, Lamacchia G, Pizzichini P, Ferranti S, Liverani A, Fontana C, Panunzi S, De Gaetano A, Lo Presti E. Recent Advances in Artificial Intelligence to Improve Immunotherapy and the Use of Digital Twins to Identify Prognosis of Patients with Solid Tumors. International Journal of Molecular Sciences. 2024 Oct 29;25(21):11588.

[54] Boatemaa R, Asare SO, Akabadin SC, Agyabeng V, Addy A. The role of AI in Enhancing Disease Surveillance and Outbreak Response in Developing Countries. Ghana Journal of Nursing and Midwifery. 2024 Nov 7;1(4):16-29.

[55] Balogun AK, Ayodimeji-Alaba H, Adebayo KT, Aminat O. Strategic procurement practices in healthcare organizations and their impact on Medicaid and Medicare cost containment.

[56] Prateek M, Rathore SP. Clinical Validation of AI Disease Detection Models—An Overview of the Clinical Validation Process for AI Disease Detection Models, and How They Can Be Validated for Accuracy and Effectiveness. AI in Disease Detection: Advancements and Applications. 2025 Jan 8:215-37.

[57] Roberts MC, Holt KE, Del Fiol G, Baccarelli AA, Allen CG. Precision public health in the era of genomics and big data. Nature Medicine. 2024 Jul;30(7):1865-73.

[58] Reddy S. Generative AI in healthcare: an implementation science informed translational path on application, integration and governance. Implementation Science. 2024 Mar 15;19(1):27.